Extracellular Matrix Associated Protein CYR61 is Linked to Prostate Cancer Development
Open accessAbstract
PURPOSE: The cancer cell microenvironment includes complex interactions between the cell and the extracellular matrix. Expression of the CCN family of extracellular matrix associated proteins is often modified in disease states. Depending on cancer type these changes are linked with enhanced or inhibited tumor growth. We characterized Cyr61 in prostate cancer. Cyr61 is an integrin binding matricellular protein with altered expression in many cancer types. MATERIALS AND METHODS: Cyr61 expression in prostate cancer, benign prostatic hyperplasia and normal tissues was evaluated by microarray analysis, quantitative real-time polymerase chain reaction and tissue microarray. Immunoblots were analyzed to assess endogenous protein expression in prostate cancer cell lines. RESULTS: On genomic analysis Cyr61 up-regulation was observed in prostate cancer tissue and in normal prostate tissue adjacent to tumor vs that in prostate donor tissue. In 174 matched tumors and normal prostate tissues adjacent to tumor tissue microarray revealed significantly up-regulated Cyr61 protein expression in cancer tissue vs normal prostate tissue adjacent to tumor. Also, increased Cyr61 expression correlated with Gleason sum 8 or greater cancer. Staining in high grade prostatic intraepithelial neoplasia was moderately up-regulated vs that in normal prostate tissue adjacent to tumor but generally less intense than in carcinoma tissue. CONCLUSIONS: In addition to the correlation with more advanced disease, the strong association between Cyr61 expression and prostate cancer supports the potential usefulness of Cyr61 as a novel biomarker for prostate cancer. This warrants further analysis to determine the mechanisms by which Cyr61 may contribute to prostate cancer development and progression.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CCN1 expression significantly correlates with stage, tumor size, lymph node positivity, and poor prognosis in several cancers, including breast cancer, prostate cancer, glioma, gastric adenocarcinoma, and squamous cell carcinoma.
“The clinical relevance of these observations is supported by the finding of a significant correlation between CCN1 expression and the stage, tumor size, lymph node positivity, and poor prognosis in several cancers, including breast cancer [142,145–148], prostate cancer [149], glioma [150], gastric adenocarcinoma [151], and squamous cell carcinoma [143].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jemal, A., Siegel, R. L., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,184 · see citing works
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,615 · see citing works
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
Gurel, B., Iwata, T., Koh, C. M., Jenkins, R., Lan, F., Dang, C., Hicks, J., Morgan, J. D., Cornish, T. C., Sutcliffe, S., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.111 · Cited by 459 · see citing works
Chen, C.-C., Chen, N., & Lau, L. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008087200 · Cited by 305 · see citing works
The Angiogenic Factor Cyr61 Activates a Genetic Program for Wound Healing in Human Skin Fibroblasts
Chen, C.-C., Mo, F.-E., & Lau, L. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107666200 · Cited by 300 · see citing works
Lin, M.-T., Chang, C.-C., Chen, S.-T., Chang, H.-L., Su, J.-L., Chau, Y.-P., & Kuo, M.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402305200 · Cited by 194 · see citing works
Grzeszkiewicz, T. M., Kirschling, D. J., Chen, N., & Lau, L. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100978200 · Cited by 162 · see citing works
Menendez, J. A., Vellon, L., Mehmi, I., Teng, P. K., Griggs, D. W., & Lupu, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208238 · Cited by 154 · see citing works
Diagnosis of adenocarcinoma in prostate needle biopsy tissue
Humphrey, P. A. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.036442 · Cited by 150 · see citing works
Cytotoxicity of TNFα is regulated by integrin‐mediated matrix signaling
Chen, C., Young, J. L., Monzon, R. I., Chen, N., Todorović, V., & Lau, L. F. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601596 · Cited by 143 · see citing works
CCN family proteins and angiogenesis: from embryo to adulthood
Kubota, S., & Takigawa, M. (2006) · Angiogenesis · doi:10.1007/s10456-006-9058-5 · Cited by 133 · see citing works
Chen, N., Leu, S.-J., Todorović, V., Lam, S. C.-T., & Lau, L. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406813200 · Cited by 132 · see citing works
Expression of Cyr61, CTGF, and WISP-1 Correlates with Clinical Features of Lung Cancer
Chen, P.-P., Li, W., Wang, Y., Zhao, S., Li, D.-Y., Feng, L.-Y., Shi, X., Koeffler, H. P., Tong, X.-J., & Xie, D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000534 · Cited by 132 · see citing works
Kulkarni, P., Pirozzi, G., Elashoff, M. R., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112191399 · Cited by 125 · see citing works
Hilfiker-Kleiner, D., Kaminski, K., Kaminska, A., Fuchs, M., Klein, G., Podewski, E., Grote, K., Kiian, I., Wollert, K. C., Hilfiker, A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000127952.90508.9d · Cited by 110 · see citing works
Haas, C. S., Creighton, C. J., Pi, X., Maine, I., Koch, A. E., Haines, G. K., Ling, S., Chinnaiyan, A. M., & Holoshitz, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21953 · Cited by 102 · see citing works
CCN proteins and cancer: two to tango
Bleau, A. (2005) · Frontiers in bioscience · doi:10.2741/1594 · Cited by 97 · see citing works
Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells
Sun, Z.-J., Wang, Y., Cai, Z., Chen, P.-P., Tong, X.-J., & Xie, D. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604712 · Cited by 95 · see citing works
Goodwin, A. C., Jadallah, S., Toubaji, A., et al. (2008) · The Prostate · doi:10.1002/pros.20735 · Cited by 95 · see citing works
Self-citationBiomarkers for Prostate Cancer Detection
Parekh, D. J., Ankerst, D. P., Troyer, D. A., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.055 · Cited by 92 · see citing works
Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer
Pilarsky, C. P., Schmidt, U., Eißrich, C., Stade, J., Froschermaier, S. E., Haase, M., Faller, G., Kirchner, T., & Wirth, M. P. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980701)36:2 · Cited by 84 · see citing works
Browne, T.-J., Hirsch, M. S., BRODSKY, G. L., et al. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.09.009 · Cited by 75 · see citing works
Holloway, S. E., Beck, A. W., Girard, L., Jaber, R., Barnett, C. C., Brekken, R. A., & Fleming, J. B. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.10.005 · Cited by 72 · see citing works
Feng, P., Wang, B., & Ren, E. C. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.06.020 · Cited by 51 · see citing works
Lin, M., Chang, C.-C., Lin, B., Yang, H., Chu, C., Wu, M., & Kuo, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706600200 · Cited by 51 · see citing works
Sakamoto, S., Yokoyama, M., Zhang, X., Kulkarni, P., Nagao, K., Hatanaka, T., Getzenberg, R. H., & Kakehi, Y. (2004) · Endocrinology · doi:10.1210/en.2003-1350 · Cited by 50 · see citing works
Self-citationLiu, H., Yang, R., Tinner, B., Choudhry, A., Schütze, N., & Chaqour, B. (2008) · Endocrinology · doi:10.1210/en.2007-1415 · Cited by 49 · see citing works
Sakamoto, S., Yokoyama, M., Aoki, M., Suzuki, K., Kakehi, Y., & Saito, Y. (2004) · The Prostate · doi:10.1002/pros.20098 · Cited by 33 · see citing works
Grzeszkiewicz, T. M. (2002) · Endocrinology · doi:10.1210/en.143.4.1441 · Cited by 23 · see citing works
Sakamoto, S., Yokoyama, M., Kulkarni, P., Tsuruha, J.-I., Masamoto, S., Getzenberg, R. H., & Kakehi, Y. (2003) · SLAS DISCOVERY · doi:10.1177/1087057103259159 · Cited by 14 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
CCN1/CYR61: the very model of a modern matricellular protein
Lau, L. F. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0778-3 · Cited by 338 · see citing works
- Authors
- D'Antonio, K. B., Toubaji, A., Albadine, R., Mondul, A. M., Platz, E. A., Netto, G. J., & Getzenberg, R. H.
- Affiliations
- The Brady Urological Institute, Baltimore, Maryland
- Johns Hopkins University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Corresponding author
- Getzenberg, Robert H.
- Venue
- Journal of Urology
- Published
- 2010-04
- Volume
- 183
- Issue
- 4
- Pages
- 1604-1610
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- PMC
- PMC3349619
- OpenAlex
- W2110768886
- Cited by
- 34
- References
- 30
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 3
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Johns Hopkins University
- National Cancer Institute (T32CA009314)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Rheumatology › Bone and Dental Protein Studies
- Keywords
- CYR61, CCN family proteins, extracellular matrix, prostate cancer, matricellular proteins, integrin binding, benign prostatic hyperplasia, Gleason score, prostatic intraepithelial neoplasia, tumor markers, tumor microenvironment, gene expression
- MeSH terms
- Adult, Aged, Humans, Male, Middle Aged, Prostatic Neoplasms, Microarray Analysis, Cysteine-Rich Protein 61
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
